Amid Uncertain World Economic Climate, China Continues to Show Growth

Warren Lammert graduated with distinction from the London School of Economics and Political Science with an MS in economic history. He has since garnered substantial experience as a financial analyst and portfolio manager that has informed not only his leadership of Granite Point Capital as its CEO and chief investment officer, but also his insights into world economic patterns over time. Moreover, Warren Lammert speaks Chinese and maintains a particular interest in the economic history of China.

In January 2019, the International Monetary Fund held to its October 2018 projections for the continuing steady economic growth of China for 2019, even as it adjusted its overall forecast for global growth downward.

The IMF forecasts that China will grow its economy by more than 6 percent in 2019. Anticipated sustained consumer demand on the domestic side, as well as Chinese government policies designed to spur such demand, are leading factors supporting that conclusion.

Even so, such an optimistic projection comes after recent slower-than-usual performance. China’s overall industrial and export activity has moderated. This comes at a time of growing trade-related tensions, with the international trade pieces of the puzzle still unclear.

The CNBC news network reported in January 2019 that China’s economy grew by only 6.6 percent over the previous year, the slowest such pace on record for almost three decades, a finding anticipated by a range of economists.

Epilepsy Research Advocate Warren Lammert

Granite Point Capital founder, CEO, and chief investment officer Warren Lammert co-founded the community website Epilepsy.com and the nonprofit Epilepsy Therapy Project in the early 2000s after discovering that his daughter was living with a rare epileptic disorder known as Dravet syndrome. While the Epilepsy Therapy Project merged with the Epilepsy Foundation in 2013, Warren Lammert continues to pursue a cure for rare epileptic disorders through his entrepreneurial endeavors and involvement in the biomedical research sector.

In this regard, Warren Lammert serves as the chairman of the board of directors of Tevard Biosciences, a gene-therapy firm in Cambridge, Massachusetts, that he co-founded in 2017. He further engages in epilepsy research in his capacity as the chairman of the board of Colorado-based Cerebral Therapeutics, a clinical-stage pharmaceutical company focused on neurologically based illnesses. Mr. Lammert also serves on the board of directors of Engage Therapeutics, which developed Staccato Alprazolam, a handheld drug device that is being tested for use as a method of treating individual epileptic seizures as they occur.

Warren Lammert has been quoted on epilepsy research-related subjects on CBS Denver and MSNBC, as well as in The New York Times. Due to his longtime dedication to the cause, he was honored in 2007 by the NYU group Finding a Cure for Epilepsy and Seizures (FACES). Mr. Lammert’s work also earned him recognition as an honoree at the Epilepsy Foundation 2013 World Changers: Art of Innovation Gala and as a recipient of the Epilepsy New England Lifetime Achievement Award.